Reports
Reports
Sale
The global anti-infectives market size was valued at USD 123.4 billion in 2023, driven by the rising prevalence of infectious diseases caused due to unhealthy environments, lack of proper sanitation, and unhygienic lifestyle. The market is anticipated to grow at a CAGR of 4.3% during the forecast period 2024-2032 to reach a value of USD 180.3 billion by 2032.
The rising prevalence of infectious diseases, particularly across the low- and middle-income countries, has led to a surge in demand for anti-infectives to curtail the spread of infection. This has been driving the market growth of anti-infectives.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
As a result of the increasing incidences of infectious agents, including bacteria, fungi, and viruses that are born from unhealthy environments lacking proper sanitation has led to the increasing incidences of diseases like diarrhoea, seasonal viral fevers, and skin infections, among others. Anti-infective agents act against the reproduction of the source of infection in the body over the course of time, and hence gradually killing the infection. Thus, the effectiveness of anti-infective agents is propelling the growth of the market.
Anti-infectives are medicines that are capable of restraining the spread of an infectious disease inside the body. These medicines can either be injected, consumed orally, or can be applied to the skin as ointments or creams.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of type, the market can be divided into:
Based on route of administration, the market can be categorised into:
The market, based on distribution channel, can be segmented into:
The EMR report looks into the regional markets of anti-infectives like North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
The market for anti-infectives is rapidly growing due to the robust investments aimed at research and development (R&D) for the production of effective anti-infectives. Owing to the increasing antimicrobial resistance to existing anti-infective agents, the pharmaceutical sector is constantly innovating and researching to produce strong anti-infectives, which is augmenting the growth of the market. In addition, robust commercialisation schemes aimed at spreading knowledge about the existence of anti-infective agents in the market is furthering the market growth of anti-infectives. Moreover, the increasing awareness regarding the avoidable risks associated with early treatment of infectious diseases is further boosting the market growth of anti-infectives globally.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The report presents a detailed analysis of the following key players in the global anti-infectives market, looking into their capacity, market share, and latest developments like capacity expansions, plant turnabouts and mergers and acquisitions:
The comprehensive report looks at the micro and macro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of the Porter’s Five Forces Model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Type |
|
Breakup by Indication |
|
Breakup by Route of Administration |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Infectious Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Infectious Disease Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Infectious Disease Epidemiology (2016-2031)
5.3 Europe Infectious Disease Epidemiology (2016-2031)
5.4 Asia-Pacific Infectious Disease Epidemiology (2016-2031)
5.5 Latin America Infectious Disease Epidemiology (2016-2031)
5.6 Middle East & Africa Infectious Disease Epidemiology (2016-2031)
6 Global Anti-Infective Market Overview
6.1 Global Anti-Infective Market Historical Value (2017-2023)
6.2 Global Anti-Infective Market Forecast Value (2024-2032)
7 Global Anti-Infective Market Landscape
7.1 Anti-Infective: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Anti-Infective: Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Indication
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by Distribution Channel
8 Anti-Infective Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Anti-Infective Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Anti-Infective Market Segmentation
11.1 Global Anti-Infective Market by Drug Type
11.1.1 Market Overview
11.1.2 Antibiotics
11.1.3 Antifungal
11.1.4 Antiviral
11.1.5 Others
11.2 Global Anti-Infective Market by Indication
11.2.1 Market Overview
11.2.2 HIV Infection
11.2.3 Pneumonia
11.2.4 Respiratory Virus Infection
11.2.5 Sepsis
11.2.6 Tuberculosis
11.2.7 Others indication
11.3 Global Anti-Infective Market by Route of Administration
11.3.1 Market Overview
11.3.2 Topical
11.3.3 Oral
11.3.4 Intravenous (IV)
11.3.5 Others
11.4 Global Anti-Infective Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online Pharmacy
11.4.5 Others
11.5 Global Anti-Infective Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Anti-Infective Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Anti-Infective Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Anti-Infective Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Anti-Infective Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Anti-Infective Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Gilead Sciences, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Sandoz International GmbH
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Pfizer Inc.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 GlaxoSmithKline plc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Abbott
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Alcon Pharmaceuticals Ltd.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Astellas Pharma Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Astrazeneca plc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Bayer Healthcare AG
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Alkem Labs
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Anti-Infective - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The global anti-infectives market reached a value of USD 123.4 billion in 2023.
The market is anticipated to grow at a CAGR of 4.3% during the forecast period of 2024-2032 to reach a value of USD 180.3 billion by 2032.
The market is being driven by the rising prevalence of infectious diseases caused due to unhealthy environments, lack of proper sanitation, and unhygienic lifestyles.
Robust investments into the pharmaceutical sector for the development of advanced anti-infectives and growing awareness regarding the early treatment of infection is leading to the growth of the market.
The major regional markets for anti-infectives are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
The major types of anti-infectives are antibacterial, antifungal, and antiviral.
The different routes of administration are topical, oral, and intravenous (IV), among others.
The various distribution channels of anti-infectives are hospital pharmacy, retail pharmacy, speciality pharmacy, and online, among others.
The major players in the industry are Gilead Sciences, Inc., Sandoz International GmbH, Pfizer Inc., GlaxoSmithKline plc., and Abbott Laboratories, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.